On 23 July 2026, Angelalign Technology Inc. held an extraordinary general meeting (EGM) at which four ordinary resolutions were approved by poll, clearing the way for new connected-transaction arrangements and revisions to the company’s equity-incentive structures.
The meeting authorised: 1) the 2027–2029 Clear Aligners Purchase and Sales Framework Agreement; 2) termination of the Post-IPO Share Option Scheme; 3) amendments and limit refresh for the Post-IPO Restricted Share Unit (RSU) Scheme; and 4) related delegation of authority to the board.
Voting results underline broad shareholder support. The framework agreement (Resolution 1) received 41.89 million votes in favour (99.99 %), while only 600 votes were cast against. Termination of the option scheme (Resolution 2) garnered 129.06 million votes for (99.99 %) versus 600 against. Amendments to the RSU Scheme (Resolution 3) passed with 37.35 million votes for (89.17 %) and 4.54 million against. The omnibus authority resolution (Resolution 4) secured 124.49 million affirmative votes (96.43 %) and 4.62 million opposing votes.
Compliance with Hong Kong listing rules led to significant abstentions. CareCapital Orthotech Limited and Noble Affluent Limited—together holding 87.39 million shares, or 51.13 % of Angelalign’s 170.90 million issued shares—abstained from voting on Resolution 1, while CareCapital also abstained on Resolution 3. In addition, trustees of the company’s employee incentive scheme abstained from voting 1.26 million shares.
All seven directors attended the meeting in person or electronically, and Tricor Investor Services Limited acted as scrutineer for the poll. The successful passage of all resolutions enables Angelalign to proceed with its three-year clear aligners supply programme and to recalibrate its post-IPO equity incentive mechanisms.
Comments